---
id: 163
title: Parvovirus B19 Infections
category: organisms
subcategory: dna_viruses
tags: [parvovirus, fifth-disease, slapped-cheek, aplastic-crisis, IVIG, hydrops-fetalis]
difficulty: medium
---

## Question

What are the key clinical syndromes of parvovirus B19? Use the **"Fifth Disease (Kids), Aplastic Crisis (Hemolysis), Hydrops Fetalis (Pregnancy) → IVIG for Severe"** framework.

## Answer

### **Parvovirus B19 Overview:**

**Transmission:** Respiratory droplets, vertical (maternal-fetal), blood products

**Pathophysiology:** **Infects erythroid precursors** (P antigen on RBC progenitors) → transient RBC aplasia

### **Clinical Syndromes:**

**Erythema Infectiosum (Fifth Disease) - Children:**

**Presentation:**
- **"Slapped cheek" rash:** Bright red facial erythema (hallmark)
- **Reticular (lacy) rash:** Trunk/extremities (appears days after facial rash)
- **Mild prodrome:** Low-grade fever, URI symptoms
- **Rash fades/recurs** over weeks (triggered by sun, heat, stress)

**Arthropathy - Adults (Especially Women):**
- **Symmetric polyarthritis:** Hands (PIP, MCP), wrists, knees, ankles
- **Mimics rheumatoid arthritis** (can be prolonged, weeks to months)
- **Rash less common** in adults

**Transient Aplastic Crisis (TAC) - Hemolytic Disorders:**

**High-Risk:**
- **Chronic hemolytic anemias:** Sickle cell disease, hereditary spherocytosis, thalassemia, G6PD deficiency
- **Baseline shortened RBC survival** + parvovirus-induced RBC aplasia → **severe anemia**

**Presentation:**
- **Sudden worsening anemia** (↓Hb, ↓reticulocyte count)
- **Fatigue, pallor, dyspnea**
- **NO rash** (viral load high, but antibody response blunted)
- **Self-limited** (7-10 days as immune response clears virus)

**Management:**
- **Transfusion support** (symptomatic anemia)
- **Supportive care**

**Pure Red Cell Aplasia (PRCA) - Immunocompromised:**

**High-Risk:**
- **HIV, transplant, leukemia, congenital immunodeficiency**
- **Chronic infection** (unable to clear virus)

**Presentation:**
- **Chronic severe anemia** (weeks to months)
- **↓Reticulocyte count, normal WBC/platelets**
- **Transfusion-dependent**

**Management:**
- **IVIG 400 mg/kg/day × 5-10 days** (provides neutralizing antibodies)
- **Monitor response:** Reticulocyte recovery in 1-2 weeks

**Hydrops Fetalis / Fetal Infection - Pregnancy:**

**Risk:**
- **Maternal infection during pregnancy** (especially 1st/2nd trimester)
- **Fetal anemia → high-output heart failure → hydrops** (ascites, pleural/pericardial effusions, skin edema)

**Outcomes:**
- **Most fetal infections asymptomatic** or mild
- **Hydrops:** ~3-10% of maternal infections
- **Fetal death:** ~10% (highest risk 9-20 weeks gestation)

**Management:**
- **Serial ultrasounds** (monitor for hydrops)
- **Intrauterine transfusion** if severe fetal anemia/hydrops
- **Many resolve spontaneously** with maternal IgG transfer

**Myocarditis:**
- **Rare** (can occur in immunocompetent or immunocompromised)
- **Acute myocarditis, dilated cardiomyopathy**

### **Diagnosis:**

**Serology (Immunocompetent):**
- **IgM anti-parvovirus B19:** Acute infection (positive 7-10 days after exposure, lasts weeks to months)
- **IgG anti-parvovirus B19:** Past infection/immunity

**PCR (Immunocompromised, TAC, Fetal Infection):**
- **Quantitative PCR (blood):** High viral load in immunocompromised, TAC (IgM may be absent)
- **Amniocentesis:** Fetal diagnosis if hydrops

### **Treatment:**

**Immunocompetent (Fifth Disease, Arthropathy):**
- **Supportive care ONLY**
- **NSAIDs** for arthropathy
- **Self-limited**

**Transient Aplastic Crisis:**
- **Transfusion support** (symptomatic anemia)
- **Supportive care** (resolves in 7-10 days)

**Pure Red Cell Aplasia (Immunocompromised):**
- **IVIG 400 mg/kg/day × 5-10 days**
- **May require repeated courses** if chronic infection

**Hydrops Fetalis:**
- **Intrauterine transfusion** (fetal anemia/hydrops)
- **Close monitoring** (many resolve spontaneously)

### **Prevention:**

**Pregnancy:**
- **Avoid exposure** to children with fifth disease (especially healthcare, daycare workers)
- **Check serology** if exposed (IgG+ = immune, no risk)

**Infection Control:**
- **Droplet precautions** during viremic phase (TAC, PRCA)
- **By the time rash appears** (fifth disease), patient no longer contagious

## Key Points

### **"Slapped Cheek" = Fifth Disease:**
- **Bright red facial rash** → lacy rash (trunk/extremities)
- **Children** (adults have arthropathy instead)
- **No longer contagious** once rash appears

### **Transient Aplastic Crisis:**
- **Sickle cell disease, hereditary spherocytosis** at risk
- **Sudden severe anemia + ↓reticulocyte count**
- **Self-limited** (7-10 days), supportive care + transfusion

### **Pure Red Cell Aplasia:**
- **Immunocompromised** (HIV, transplant)
- **Chronic anemia** (transfusion-dependent)
- **IVIG curative** (provides neutralizing antibodies)

### **Hydrops Fetalis:**
- **Maternal infection → fetal anemia → hydrops**
- **Risk highest 9-20 weeks gestation**
- **Intrauterine transfusion** if severe

### **Arthropathy in Adults:**
- **Symmetric polyarthritis** (hands, wrists, knees)
- **Mimics RA** (can be prolonged)
- **NSAIDs + supportive care**

### **Clinical Pearls:**
- **Fifth disease:** "Slapped cheek" rash in child (no longer contagious once rash appears)
- **TAC:** Sudden severe anemia in sickle cell/hemolysis patient
- **PRCA:** Chronic anemia in immunocompromised → IVIG curative
- **Pregnancy:** Risk of hydrops fetalis (3-10%), intrauterine transfusion if severe
- **Arthropathy:** Symmetric polyarthritis in adult women (mimics RA)

## Sources

- [CDC: Parvovirus B19 Guidelines 2024]
- [ACOG: Parvovirus B19 in Pregnancy 2024]

## Media

N/A
